{"title":"补充omega-3多不饱和脂肪酸的肠内免疫营养对重型颅脑损伤患者炎症反应及肠黏膜屏障功能的影响","authors":"Xiangrong Chen, Cui'e Wang, Baoyuan Xie, Rongrong Zhu, Jinxia Liu, Tian-zao Huang","doi":"10.3760/CMA.J.ISSN.1674-635X.2018.01.003","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effects of enteral immunonutrition supplemented with omega-3 polyunsaturated fatty acid (ω-3 PUFA) on inflammatory response, intestinal mucosal barrier function and the prognosis in patients with severe traumatic brain injury (sTBI). \n \n \nMethods \n122 patients of sTBI hospitalized between January 2015 and December 2016 were randomly divided into experimental group (ω-3 PUFA, n=61) and control group (n=61). The serum levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and neuron specific enolase (NSE) were tested with enzyme linked immunosorbent assay. Meanwhile, D-lactate acid and intestinal fat acid binding protein (I-FABP) were evaluated by enzymology spectrophotometer method. After 14 days of treatment, the Glasgow Coma Scale (GCS) scores, Acute Physiology and Chronic Health Evaluation (APACHE) Ⅱ scores and prognoses of both groups were compared. \n \n \nResults \nThe serum levels of inflammatory factors (TNF-α and IL-6), intestinal mucosal barrier function indicators (D-lactate acid and I-FABP) and NSE proteins significantly increased after sTBI (P=0.01). Compared with the control group, the experimental group on day 3 had significantly lower serum levels of inflammatory factors [TNF-α: (107.77±19.79)μg/L vs. (151.76±21.65)μg/L, P=0.01; IL-6: (76.85±7.15)μg/L vs. (105.27±10.12)μg/L, P=0.01] and intestinal mucosal barrier function indicators [D-lactate: (69.81±6.32)μg/L vs. (89.80±8.75)μg/L, P=0.03; I-FABP: (40.81±6.73)μg/L vs. (56.60±8.58)μg/L, P=0.01]. On day 7, the experimental group had significantly lower expression of NSE proteins than the control group [(13.63±2.53)μg/L vs. (19.12±3.00)μg/L, P=0.02]. The experimental group received better prognosis compared to the control group on day 14 [GCS scores: (9.74±0.76)vs. (8.44±0.53), P=0.04; APACHE Ⅱ scores: (14.67±1.37)vs. (17.53±1.47), P=0.03]. The experimental group also had fewer days in hospitalization [(19.37±2.27)d vs. (25.42±2.61)d, P=0.01]. \n \n \nConclusion \nEnteral immunonutrition supplemented with ω-3 PUFA can effectively regulate the inflammatory response, and reduce impairment to the intestinal mucosal barrier function and damage to neurons in patients with sTBI. \n \n \nKey words: \nCraniocerebral trauma; Unsaturated fatty acids; Inflammatory response; Intestinal mucosal barrier","PeriodicalId":9877,"journal":{"name":"中华临床营养杂志","volume":"26 1","pages":"17-21"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Effects of enteral immunonutrition supplemented with omega-3 polyunsaturated fatty acid on inflammatory response and intestinal mucosal barrier function in patients with severe traumatic brain injury\",\"authors\":\"Xiangrong Chen, Cui'e Wang, Baoyuan Xie, Rongrong Zhu, Jinxia Liu, Tian-zao Huang\",\"doi\":\"10.3760/CMA.J.ISSN.1674-635X.2018.01.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo investigate the effects of enteral immunonutrition supplemented with omega-3 polyunsaturated fatty acid (ω-3 PUFA) on inflammatory response, intestinal mucosal barrier function and the prognosis in patients with severe traumatic brain injury (sTBI). \\n \\n \\nMethods \\n122 patients of sTBI hospitalized between January 2015 and December 2016 were randomly divided into experimental group (ω-3 PUFA, n=61) and control group (n=61). The serum levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and neuron specific enolase (NSE) were tested with enzyme linked immunosorbent assay. Meanwhile, D-lactate acid and intestinal fat acid binding protein (I-FABP) were evaluated by enzymology spectrophotometer method. After 14 days of treatment, the Glasgow Coma Scale (GCS) scores, Acute Physiology and Chronic Health Evaluation (APACHE) Ⅱ scores and prognoses of both groups were compared. \\n \\n \\nResults \\nThe serum levels of inflammatory factors (TNF-α and IL-6), intestinal mucosal barrier function indicators (D-lactate acid and I-FABP) and NSE proteins significantly increased after sTBI (P=0.01). Compared with the control group, the experimental group on day 3 had significantly lower serum levels of inflammatory factors [TNF-α: (107.77±19.79)μg/L vs. (151.76±21.65)μg/L, P=0.01; IL-6: (76.85±7.15)μg/L vs. (105.27±10.12)μg/L, P=0.01] and intestinal mucosal barrier function indicators [D-lactate: (69.81±6.32)μg/L vs. (89.80±8.75)μg/L, P=0.03; I-FABP: (40.81±6.73)μg/L vs. (56.60±8.58)μg/L, P=0.01]. On day 7, the experimental group had significantly lower expression of NSE proteins than the control group [(13.63±2.53)μg/L vs. (19.12±3.00)μg/L, P=0.02]. The experimental group received better prognosis compared to the control group on day 14 [GCS scores: (9.74±0.76)vs. (8.44±0.53), P=0.04; APACHE Ⅱ scores: (14.67±1.37)vs. (17.53±1.47), P=0.03]. The experimental group also had fewer days in hospitalization [(19.37±2.27)d vs. (25.42±2.61)d, P=0.01]. \\n \\n \\nConclusion \\nEnteral immunonutrition supplemented with ω-3 PUFA can effectively regulate the inflammatory response, and reduce impairment to the intestinal mucosal barrier function and damage to neurons in patients with sTBI. \\n \\n \\nKey words: \\nCraniocerebral trauma; Unsaturated fatty acids; Inflammatory response; Intestinal mucosal barrier\",\"PeriodicalId\":9877,\"journal\":{\"name\":\"中华临床营养杂志\",\"volume\":\"26 1\",\"pages\":\"17-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华临床营养杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1674-635X.2018.01.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华临床营养杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-635X.2018.01.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
Effects of enteral immunonutrition supplemented with omega-3 polyunsaturated fatty acid on inflammatory response and intestinal mucosal barrier function in patients with severe traumatic brain injury
Objective
To investigate the effects of enteral immunonutrition supplemented with omega-3 polyunsaturated fatty acid (ω-3 PUFA) on inflammatory response, intestinal mucosal barrier function and the prognosis in patients with severe traumatic brain injury (sTBI).
Methods
122 patients of sTBI hospitalized between January 2015 and December 2016 were randomly divided into experimental group (ω-3 PUFA, n=61) and control group (n=61). The serum levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and neuron specific enolase (NSE) were tested with enzyme linked immunosorbent assay. Meanwhile, D-lactate acid and intestinal fat acid binding protein (I-FABP) were evaluated by enzymology spectrophotometer method. After 14 days of treatment, the Glasgow Coma Scale (GCS) scores, Acute Physiology and Chronic Health Evaluation (APACHE) Ⅱ scores and prognoses of both groups were compared.
Results
The serum levels of inflammatory factors (TNF-α and IL-6), intestinal mucosal barrier function indicators (D-lactate acid and I-FABP) and NSE proteins significantly increased after sTBI (P=0.01). Compared with the control group, the experimental group on day 3 had significantly lower serum levels of inflammatory factors [TNF-α: (107.77±19.79)μg/L vs. (151.76±21.65)μg/L, P=0.01; IL-6: (76.85±7.15)μg/L vs. (105.27±10.12)μg/L, P=0.01] and intestinal mucosal barrier function indicators [D-lactate: (69.81±6.32)μg/L vs. (89.80±8.75)μg/L, P=0.03; I-FABP: (40.81±6.73)μg/L vs. (56.60±8.58)μg/L, P=0.01]. On day 7, the experimental group had significantly lower expression of NSE proteins than the control group [(13.63±2.53)μg/L vs. (19.12±3.00)μg/L, P=0.02]. The experimental group received better prognosis compared to the control group on day 14 [GCS scores: (9.74±0.76)vs. (8.44±0.53), P=0.04; APACHE Ⅱ scores: (14.67±1.37)vs. (17.53±1.47), P=0.03]. The experimental group also had fewer days in hospitalization [(19.37±2.27)d vs. (25.42±2.61)d, P=0.01].
Conclusion
Enteral immunonutrition supplemented with ω-3 PUFA can effectively regulate the inflammatory response, and reduce impairment to the intestinal mucosal barrier function and damage to neurons in patients with sTBI.
Key words:
Craniocerebral trauma; Unsaturated fatty acids; Inflammatory response; Intestinal mucosal barrier
期刊介绍:
The Chinese Journal of Clinical Nutrition was founded in 1993. It is the first professional academic journal (bimonthly) in my country co-sponsored by the Chinese Medical Association and the Chinese Academy of Medical Sciences to disseminate information on clinical nutrition support, nutrient metabolism, the impact of nutrition support on outcomes and "cost-effectiveness", as well as translational medicine and nutrition research. It is also a professional journal of the Chinese Medical Association's Parenteral and Enteral Nutrition Branch.
The purpose of the Chinese Journal of Clinical Nutrition is to promote the rapid dissemination of knowledge on nutrient metabolism and the rational application of parenteral and enteral nutrition, focusing on the combination of multidisciplinary and multi-regional field investigations and clinical research. It mainly reports on nutritional risk screening related to the indications of parenteral and enteral nutrition support, "cost-effectiveness" research on nutritional drugs, consensus on clinical nutrition, guidelines, expert reviews, randomized controlled studies, cohort studies, glycoprotein and other nutrient metabolism research, systematic evaluation of clinical research, evidence-based case reports, special reviews, case reports and clinical experience exchanges, etc., and has a special column on new technologies related to the field of clinical nutrition and their clinical applications.